Research ID
hum0210-v2Release info
Latest
Research title
Comprehensive genomic analysis of hematological malignancies
Research overview
- Aims
- To perform comprehensive genomic analysis of hematological malignancies, including drug response analysis using disease models, to elucidate molecular pathogenesis and contribute to improved treatment outcomes.
- Methods
- Whole exome sequencing was performed for both acute myeloid leukemia cells and mediastinal germ cell tumor cells, and somatic mutations of both tumor cells were identified, using normal buccal cells as a control. RNA-seq was performed for tumour cells harvested from 5 adult T-cell leukemia/lymphoma PDX models (vehicle and MALT1 inhibitor CRD-1441551-treated, n=3 per condition).
- Participants/materials
- Patient with concomitant acute myeloid leukemia and mediastinal germ cell tumor, 5 PDX models of adult T-cell leukemia/lymphoma, each established from a separate patient (one model per patient).
- URL
- N/A
Datasets
| Cart | Dataset ID | Type of data | Analysis method | Access criteria | Date published |
|---|---|---|---|---|---|
| JGAD000297 | NGS (Exome) |
| Controlled-access (Type I) | 2020-09-28 | |
| JGAD001065 | NGS (RNA-seq) |
| Controlled-access (Type I) | 2026-08-03 |
Data provider
- Principal investigator
- Kazuya Shimoda
- Affiliation
- Division of Gastroenterology and Hematology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki
Research projects
| Name | URL |
|---|---|
N/A | N/A |
Grants
| Name | Title | Project number |
|---|---|---|
National Cancer Center Research and Development Funds | Development of a comprehensive genomic profiling assay for hematological malignancies. |
|
Grant-in-Aid for Clinical Research from University of Miyazaki Hospital | Establishment of a method to identify high-risk groups for the development of hematological tumors. |
|
Medical Research and Development Programs Focused on Technology Transfers: Development of Advanced Measurement and Analysis Systems (AMED-SENTAN), Japan Agency for Medical Research and Development (AMED) | Novel Taylor-made therapy for adult T-cell leukemia/lymphoma |
|
Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED) | Establishment of precision medicine for ATL and identification of high risk HTLV-1 carriers |
|
Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED) | Development of MALT1 inhibitor for intractable lymphomas |
|
Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED) | Establishment of personalized medicine for ATL based on the understanding of the genomic landscape and clonal structure |
|
Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED) | Identification of novel therapeutic targets and development of personalized medicine for ATL |
|
KAKENHI Grant-in-Aid for Scientific Research (C) | Development of an ATL mouse model and the establishment of precision medicine that accounts for the diversity of tumor survival signals |
|
KAKENHI Grant-in-Aid for Scientific Research (B) | Elucidation of the mechanism of ATL development through interactions with microenvironmental cells, and development of therapeutic strategies based on molecular vulnerabilities |
|
Related publications
| Title | DOI | Dataset ID |
|---|---|---|
TP53 and PTEN mutations were shared in concurrent germ cell tumor and acute megakaryoblastic leukemia. | ||
The requirement of MALT1 activity for the growth of adult T-cell leukemia/lymphoma |
Controlled access users
No use of the controlled access data has been recorded.